Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Teva Pharmaceutical Industries Limited's quarterly P/E stands at 24.3x, up 13.8% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 26.1% YoY to 13.7x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 26.23 | 24.29 | 19.03 | 13.65 | 17.46 | 21.35 | — | — | — | — | 6.37 | 36.17 | — |
| — | +13.8% | — | — | — | — | — | — | — | — | — | -10.4% | — | |
| P/S Ratio | 2.12 | 2.23 | 1.94 | 1.31 | 1.16 | 1.14 | 1.48 | 1.18 | 1.11 | 1.04 | 0.67 | 0.75 | 0.54 |
| — | +94.8% | +31.6% | +11.3% | +5.4% | +10.3% | +121.7% | +56.8% | +103.3% | +53.9% | +2.1% | +19.7% | -1.4% | |
| P/B Ratio | 4.67 | 4.31 | 4.63 | 3.24 | 2.85 | 2.84 | 4.37 | 3.20 | 2.81 | 2.10 | 1.46 | 1.54 | 1.09 |
| — | +51.8% | +6.0% | +1.4% | +1.5% | +35.3% | +198.9% | +107.5% | +156.4% | +83.3% | +24.0% | +62.5% | +28.8% | |
| P/FCF | 31.93 | — | 9.01 | 25.23 | 37.13 | — | 14.00 | 9.37 | 767.14 | — | 2.79 | — | 10.28 |
| — | — | -35.6% | +169.4% | -95.2% | — | +402.3% | — | +7358.9% | — | -8.6% | — | — | |
| EV / EBITDA | 15.98 | 13.66 | 22.52 | 8.49 | 12.33 | 10.83 | 41.41 | 43.72 | 34.52 | 151.82 | 7.04 | 11.81 | — |
| — | +26.1% | -45.6% | -80.6% | -64.3% | -92.9% | +487.8% | +270.1% | — | +514.4% | — | +23.0% | — | |
| EV / EBIT | 23.40 | 19.07 | 33.89 | 11.23 | 21.44 | 15.92 | 11.13 | — | — | — | 5.75 | 21.53 | 9.99 |
| — | +19.8% | +204.6% | — | — | — | +93.4% | — | — | — | — | +26.6% | -9.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Teva Pharmaceutical Industries Limited's operating margin was 16.4% in Q1 2026, up 10.0 pp QoQ and up 3.0 pp YoY. The trailing four-quarter average of 13.3% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.8% | 49.5% | 56.4% | 51.4% | 50.3% | 48.2% | 50.1% | 49.6% | 48.6% | 46.4% | 54.2% | 48.1% | 46.3% |
| — | +2.7% | +12.5% | +3.7% | +3.6% | +4.0% | -7.5% | +3.2% | +5.0% | +7.3% | +18.9% | +3.6% | -2.3% | |
| Operating Margin | 12.5% | 16.4% | 6.4% | 19.7% | 10.9% | 13.3% | -0.7% | -1.2% | -0.1% | -5.7% | 17.0% | 8.9% | -16.9% |
| — | +22.8% | +1028.7% | +1771.8% | +9172.1% | +333.7% | -104.0% | -113.2% | +99.3% | -1507.5% | +177.0% | -23.3% | +32.7% | |
| Net Margin | 8.2% | 9.3% | 10.2% | 9.7% | 6.8% | 5.5% | -5.1% | -10.1% | -20.3% | -3.6% | 10.4% | 1.8% | -22.5% |
| — | +68.5% | +298.6% | +195.8% | +133.2% | +251.1% | -149.4% | -663.0% | +9.6% | +39.4% | +133.0% | +15.1% | -266.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.7% | 4.6% | 6.3% | 6.1% | 4.3% | 3.6% | -3.6% | -6.8% | -12.0% | -1.8% | 5.9% | 0.9% | -10.7% |
| — | +28.0% | +276.5% | +191.1% | +135.9% | +301.2% | -160.5% | -844.4% | -12.2% | +30.6% | +143.9% | +56.6% | -362.7% | |
| ROA | 3.5% | 0.9% | 1.2% | 1.1% | 0.7% | 0.6% | -0.5% | -1.1% | -2.0% | -0.3% | 1.1% | 0.2% | -2.0% |
| — | +65.9% | +322.5% | +202.9% | +135.7% | +270.8% | -149.5% | -749.3% | +0.2% | +35.9% | +139.1% | +30.4% | -303.8% | |
| ROIC | 7.7% | 2.3% | 1.0% | 3.0% | 1.6% | 1.9% | -0.1% | -0.2% | -0.0% | -0.7% | 2.2% | 1.0% | -1.8% |
| — | +22.3% | +1110.3% | +1877.2% | +10045.9% | +380.8% | -104.5% | -116.8% | +99.1% | -1759.2% | +198.3% | -5.9% | +20.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Teva Pharmaceutical Industries Limited's Debt/EBITDA ratio is 19.0x, down from 31.0x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.20 | 2.05 | 2.20 | 2.36 | 2.56 | 2.70 | 3.16 | 3.02 | 2.88 | 2.64 | 2.48 | 2.70 | 2.73 |
| — | -24.0% | -30.5% | -22.0% | -11.1% | +2.2% | +27.4% | +11.7% | +5.7% | +8.2% | -1.1% | +19.0% | +19.3% | |
| Debt / EBITDA | 5.50 | 18.98 | 31.04 | 15.11 | 24.82 | 22.20 | 75.33 | 92.67 | 74.50 | 369.22 | 19.72 | 32.37 | — |
| — | -14.5% | -58.8% | -83.7% | -66.7% | -94.0% | +282.0% | +186.2% | — | +410.8% | — | +10.8% | — | |
| Current Ratio | 1.04 | 1.01 | 1.04 | 1.11 | 1.06 | 1.03 | 0.98 | 0.89 | 0.89 | 0.89 | 1.02 | 1.00 | 1.02 |
| — | -1.9% | +5.7% | +24.2% | +19.3% | +15.9% | -3.8% | -11.0% | -12.6% | -19.3% | -3.0% | +1.0% | -7.7% | |
| Quick Ratio | 0.80 | 0.78 | 0.80 | 0.82 | 0.77 | 0.74 | 0.75 | 0.61 | 0.59 | 0.61 | 0.69 | 0.65 | 0.67 |
| — | +4.9% | +7.3% | +35.3% | +30.1% | +22.6% | +7.9% | -6.4% | -12.3% | -14.6% | -3.5% | -1.7% | -8.7% | |
| Interest Coverage | 2.34 | 3.17 | 1.27 | 4.09 | 2.00 | 2.31 | 1.17 | -0.19 | -0.05 | -0.87 | 4.81 | 1.23 | 2.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into TEVA consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TEVA stock.
Teva Pharmaceutical Industries Limited's current P/E is 26.2x. The average P/E over the last 4 quarters is 18.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Teva Pharmaceutical Industries Limited's current operating margin is 12.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Teva Pharmaceutical Industries Limited's business trajectory between earnings reports.